Medigen Vaccine Biologics : Clarification on media reports

Close

Today's Information

Provided by: Medigen Vaccine Biologics Corporation
SEQ_NO	1	Date of announcement	2022/06/29	Time of announcement	11:02:28
Subject	Clarification on media reports
Date of events	2022/06/29	To which item it meets	paragraph 53
Statement	1.Date of occurrence of the event:2022/06/29 2.Company name: Medigen Vaccine Biologics Corp. 3.Relationship to the Company (please enter "head office" or "subsidiaries"):head office 4.Reciprocal shareholding ratios:N/A 5.Name of the reporting media:Economic Daily News 2022/06/29 A06 6.Content of the report: MVC has filed New Drug Application (NDA) to Taiwan Food and Drug Administration of the Ministry of Health and Welfare, and expected to get the approval in the second half of this year. 7.Cause of occurrence: The company's response to the media reports is explained as follows: The MVC quadrivalent influenza vaccine has submitted the New Drug Application to Taiwan Food and Drug Administration on January 11 this year. The review is currently in progress and the actual review results will be announced in accordance with regulations. This project is in cooperation with GC Pharma. GC Pharma produces the vaccine bulk, and then MVC conducts fill-and-finish, quality control release, and applies for drug certificate under MVC's brand. MVC will join the domestic quadrivalent influenza vaccine supply after receiving the approval. 8.Countermeasures:None 9.Any other matters that need to be specified:None